Literature DB >> 32283203

A toxic palmitoylation of Cdc42 enhances NF-κB signaling and drives a severe autoinflammatory syndrome.

Bahia Bekhouche1, Aurore Tourville2, Yamini Ravichandran3, Rachida Tacine2, Laurence Abrami4, Michael Dussiot1, Andrea Khau-Dancasius1, Olivia Boccara5, Meriem Khirat2, Marianne Mangeney2, Florent Dingli6, Damarys Loew6, Batiste Boëda7, Pénélope Jordan8, Thierry Jo Molina9, Nathalia Bellon5, Sylvie Fraitag10, Smail Hadj-Rabia5, Stéphane Blanche11, Anne Puel12, Sandrine Etienne-Manneville7, F Gisou van der Goot4, Jacqueline Cherfils13, Olivier Hermine14, Jean-Laurent Casanova15, Christine Bodemer16, Asma Smahi17, Jérôme Delon18.   

Abstract

Entities:  

Year:  2020        PMID: 32283203     DOI: 10.1016/j.jaci.2020.03.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  13 in total

Review 1.  RHO GTPases: from new partners to complex immune syndromes.

Authors:  Rana El Masri; Jérôme Delon
Journal:  Nat Rev Immunol       Date:  2021-02-05       Impact factor: 53.106

2.  Trapping of CDC42 C-terminal variants in the Golgi drives pyrin inflammasome hyperactivation.

Authors:  Masahiko Nishitani-Isa; Kojiro Mukai; Yoshitaka Honda; Hiroshi Nihira; Takayuki Tanaka; Hirofumi Shibata; Kumi Kodama; Eitaro Hiejima; Kazushi Izawa; Yuri Kawasaki; Mitsujiro Osawa; Yu Katata; Sachiko Onodera; Tatsuya Watanabe; Takashi Uchida; Shigeo Kure; Junko Takita; Osamu Ohara; Megumu K Saito; Ryuta Nishikomori; Tomohiko Taguchi; Yoji Sasahara; Takahiro Yasumi
Journal:  J Exp Med       Date:  2022-04-28       Impact factor: 17.579

3.  Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.

Authors:  Stuart G Tangye; Waleed Al-Herz; Aziz Bousfiha; Charlotte Cunningham-Rundles; Jose Luis Franco; Steven M Holland; Christoph Klein; Tomohiro Morio; Eric Oksenhendler; Capucine Picard; Anne Puel; Jennifer Puck; Mikko R J Seppänen; Raz Somech; Helen C Su; Kathleen E Sullivan; Troy R Torgerson; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2022-06-24       Impact factor: 8.542

4.  The Growing Spectrum of Human Diseases Caused by Inherited CDC42 Mutations.

Authors:  Helen C Su; Jordan S Orange
Journal:  J Clin Immunol       Date:  2020-05       Impact factor: 8.317

5.  Progressive decline of T and B cell numbers and function in a patient with CDC42 deficiency.

Authors:  Paria Kashani; Ashish Marwaha; Stephen Feanny; Vy Hong-Diep Kim; Adelle R Atkinson; Matilde Leon-Ponte; Roberto Mendoza-Londono; Eyal Grunebaum
Journal:  Immunol Res       Date:  2021-01-06       Impact factor: 2.829

Review 6.  Inborn errors of immunity with atopic phenotypes: A practical guide for allergists.

Authors:  Riccardo Castagnoli; Vassilios Lougaris; Giuliana Giardino; Stefano Volpi; Lucia Leonardi; Francesco La Torre; Silvia Federici; Stefania Corrente; Bianca Laura Cinicola; Annarosa Soresina; Caterina Cancrini; Gian Luigi Marseglia; Fabio Cardinale
Journal:  World Allergy Organ J       Date:  2021-02-22       Impact factor: 4.084

Review 7.  Primary immune regulatory disorders: a growing universe of immune dysregulation.

Authors:  Alice Y Chan; Troy R Torgerson
Journal:  Curr Opin Allergy Clin Immunol       Date:  2020-12

Review 8.  Protein Lipidation by Palmitate Controls Macrophage Function.

Authors:  Jeroen Guns; Sam Vanherle; Jerome J A Hendriks; Jeroen F J Bogie
Journal:  Cells       Date:  2022-02-06       Impact factor: 6.600

Review 9.  Compromised Protein Prenylation as Pathogenic Mechanism in Mevalonate Kinase Deficiency.

Authors:  Frouwkje A Politiek; Hans R Waterham
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 10.  Human Autoinflammatory Diseases Mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18.

Authors:  Sara Alehashemi; Raphaela Goldbach-Mansky
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.